<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506892</url>
  </required_header>
  <id_info>
    <org_study_id>RFA-AT-21-001</org_study_id>
    <nct_id>NCT04506892</nct_id>
  </id_info>
  <brief_title>Quantitation of Glymphatic Functioning in Sleep and Meditative States</brief_title>
  <official_title>Quantitation of Glymphatic Functioning in Sleep and Meditative States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This involves development and application of magnetic resonance imaging (MRI) methods for&#xD;
      visualizing hemodynamic and metabolic relationships in healthy volunteers with advanced&#xD;
      meditation experience.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CSF flow change</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Using MRI to assess the change in CSF flow in awake, sleep deprived, and meditative states</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG changes</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Looking at brain wave changes before and after intervention in Alpha, Beta, and Delta waves associated with light to deep sleep. The lowest bandwidth for alpha waves is 8 while the highest is 12. The lowest bandwidth for Beta waves is 13 Hz while the highest is 30 Hz. The lowest bandwidth for Delta waves is .4 Hz and the highest is 4 Hz.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Adept Meditators</arm_group_label>
    <description>Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population is a healthy group of &quot;adept meditators&quot; (based on minimum meditation lifetime&#xD;
        experience of &gt;1000 hours and a self reported proficiency score of &gt;3 out of 5)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 14-45&#xD;
&#xD;
          -  &quot;Adept meditator status&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any non-MR compatible material implant, or contraindication to MR scanning&#xD;
&#xD;
          -  Claustrophobia or inability to lie still for prolonged periods of time&#xD;
&#xD;
          -  Participants with a recent (less than 2 months) infection, tattoo, or wound&#xD;
&#xD;
          -  No consumption of stimulants or alcohol within 12 hours of the study visit&#xD;
&#xD;
          -  clinical diagnosis of any major neurological or psychological condition&#xD;
&#xD;
          -  Taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, MAO&#xD;
             inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Claassen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Claassen, MD</last_name>
    <phone>6153226103</phone>
    <email>daniel.claassen@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ciaran Considine, PhD</last_name>
    <email>ciaran.considine@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-3160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Claassen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>glymphatic system</keyword>
  <keyword>meditation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

